Postdoctoral Research Scientist (Signalling)
Babraham Institute
Cambridge, United Kingdom
This full-time, fixed-term post offers an inspiring opportunity to join the renowned Babraham Institute and contribute to pioneering research in cellular signalling with broad implications for understanding biological processes related to health and ageing. The successful candidate will become part of a vibrant research environment in the Institute’s Signalling Programme, working on projects that investigate fundamental mechanisms of cell signalling. You will work alongside interdisciplinary teams in state-of-the-art facilities, advancing scientific knowledge and contributing to academic outputs that resonate across the life sciences community. The role supports independent and collaborative research, placing emphasis on innovative experimental design and deep engagement with complex biological questions that underpin health and disease.
Eligibility Criteria
Applicants should hold a PhD (or have submitted their thesis) in biochemistry, cellular or molecular biology, or a closely related discipline. Demonstrated research capability through previous work and a commitment to rigorous experimental inquiry are essential for this position.
Required Expertise, Skills
Candidates are expected to bring hands-on experience in cell signalling research. Skills in relevant laboratory techniques, conceptual understanding of key signalling pathways, and the ability to analyse and interpret experimental data are important. The role also values strong communication skills and the ability to contribute to scientific writing and presentations within the research group and at conferences.
Salary Details
The salary for this post is typical of competitive research scientist positions in the UK, with remuneration aligned to experience and established pay scales for postdoctoral researchers. Precise figures are determined by institutional guidelines and the candidate’s qualifications.
Application Deadline
Applications close on Wednesday, 25 February 2026.